Skip to main content
    K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.10
    +0.05 (+0.45%)

    Market Cap: $219.09M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(13/26)
    Avg Surprise
    +1361.01%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.86
    Range$-1.53 - $-0.56
    4 analysts
    EPS Revisions
    1
    0
    7d
    3
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.34+36.1%
    60d ago$-1.30+33.7%
    30d ago$-1.30+33.7%
    7d ago$-0.79-9.1%
    Current$-0.86
    Revenue Consensus
    $14M
    Range$350000 - $20M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.20
    Range$-2.88 - $-1.60
    5 analysts
    Revenue Consensus
    $-718560
    Range$-15218420 - $4M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.20---
    Sep 26EST
    		-$-0.86---
    Jun 26
    Reported Aug 3
    		$-1.45$-1.25-16.00%Miss-90.8%
    Mar 26
    Reported May 14
    		$-1.21$-0.73-66.23%Miss-133.4%
    Dec 25
    Reported Mar 4
    		$-0.86$-0.45-91.11%Miss+24.6%
    Sep 25
    Reported Nov 5
    		$-0.18N/A+83.78%Beat+87.2%
    Jun 25
    Reported Aug 6
    		$-0.76$-1.13+32.74%Beat+39.2%
    Mar 25
    Reported May 6
    		$3.62$0.01+36100.00%Beat+399.2%
    Dec 24
    Reported Feb 26
    		$-1.14$-0.43-166.98%Miss+14.9%
    Sep 24
    Reported Nov 6
    		$-1.41$-1.28-10.16%Miss-6.0%
    Jun 24
    Reported Aug 7
    		$-1.25$-1.25+0.00%Beat+1.6%
    Mar 24
    Reported May 8
    		$-1.21$-1.33+9.02%Beat+4.0%
    Dec 23
    Reported Feb 28
    		$-1.34$-1.37+2.19%Beat-22.9%
    Sep 23
    Reported Nov 6
    		$-1.33$-1.35+1.48%Beat-44.6%
    Jun 23
    Reported Aug 7
    		$-1.27$-1.35+5.93%Beat-12.4%
    Mar 23
    Reported May 4
    		$-1.26$-1.14-10.53%Miss-24.8%
    Dec 22
    Reported Mar 3
    		$-1.09$-1.10+0.91%Beat-263.3%
    Sep 22
    Reported Nov 3
    		$-0.92$-1.26+26.98%Beat-5.7%
    Jun 22
    Reported Aug 4
    		$-1.13$-1.07-5.61%Miss-68.7%
    Mar 22
    Reported May 5
    		$-1.01$-0.86-17.44%Miss-48.5%
    Dec 21
    Reported Mar 9
    		$-0.30N/A+67.39%Beat+38.8%
    Sep 21
    Reported Nov 4
    		$-0.87$-0.72-20.83%Miss-45.0%
    Jun 21
    Reported Aug 5
    		$-0.67$-0.65-3.08%Miss-8.1%
    Mar 21
    Reported May 6
    		$-0.68$-0.58-17.24%Miss+86.7%
    Dec 20
    Reported Mar 25
    		$-0.49$-0.57+14.04%Beat-
    Sep 20
    Reported Nov 10
    		$-0.60$-0.59-1.69%Miss-
    Jun 20
    Reported Aug 13
    		$-0.62$-0.67+7.46%Beat-
    Mar 20
    Reported Apr 8
    		$-5.11$-0.80-538.75%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3.00EV/EBITDAN/A
    Price/FCF-4.53xFCF Yield-22.06%
    Profitability
    Profit Margin0.00%Operating Margin-656.00%
    ROE-17.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio21.96xQuick Ratio21.96x
    Trading Statistics
    Beta1.12Avg Volume192.12K
    52-Week High$22.5552-Week Low$9.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.37
    SMA 20$11.40
    SMA 50$11.16
    SMA 200$12.49
    EMA 10$11.32
    EMA 20$11.33
    EMA 50$11.20
    EMA 200$12.17

    MACD

    Line: 0.03Signal: 0.08Hist: -0.05

    ADX

    ADX: 15.6+DI: 20.5-DI: 18.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$10.92

    Bollinger Bands

    Upper Band$11.91
    Lower Band$10.90
    %B Position886%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    46.8

    Momentum Oscillators

    Stoch %K21.8
    Stoch %D36.6
    Williams %R-80.0
    ROC (10d)-1.4%
    Momentum-0.16
    CCI (20d)-87.9
    MFI (14d)48.1

    Volatility Measures

    ATR (14d)$0.51(4.6%)
    StdDev (20d)0.25
    Hist Vol36.1%(Moderate)

    Volume Flow

    VWAP$11.16
    OBV11.2M
    AD Line11.6M
    CMF (20d)0.088

    Volume Metrics

    Avg Vol (20d)183.9K
    Vol Ratio0.5x
    VWMA (20d)$11.42

    Pivot Points

    R3$11.64
    R2$11.47
    R1$11.26
    Pivot Point$11.09
    S1$10.88
    S2$10.71
    S3$10.50

    Advanced Oscillators

    TSI2.13
    Ultimate Osc48.3
    KST21.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$367,000$385,000$14.26M$18.17M$211.25M$3.04M$388,000$37,000$83,000$143,000$8,000
    Cost of Revenue$0$0$400,000$0$0$0$332,000$0$0$0$247,000$0
    Gross Profit$0$367,000$385,000$14.26M$18.17M$211.25M$3.04M$388,000$37,000$83,000$143,000$8,000
    Operating Expenses$30.94M$26.24M$29.66M$29.65M$57.98M$59.21M$56.30M$59.05M$50.48M$48.57M$46.60M$43.29M
    R&D$22.33M$16.10M$17.91M$19.52M$43.50M$48.71M$45.63M$49.23M$40.52M$38.26M$37.49M$34.14M
    SG&A$8.61M$10.15M$11.74M$10.13M$14.48M$10.50M$10.66M$9.82M$9.96M$10.31M$9.11M$9.15M
    Operating Income$-30,937,000$-25,877,000$-29,270,000$-15,384,000$-39,817,000$152.04M$-53,254,000$-58,657,000$-50,439,000$-48,483,000$-46,455,000$-43,280,000
    Interest Income$2.29M$2.33M$4.02M$6.93M$7.12M$6.79M$6.52M$5.79M$5.38M$5.81M$3.76M$3.91M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-28,710,000$-23,708,000$-24,975,000$-8,704,000$-32,918,000$158.49M$-45,726,000$-52,956,000$-45,257,000$-43,114,000$-40,243,000$-39,440,000
    Income Tax Expense$0$0$-1,514,000$-1,424,000$-2,222,000$10.04M$300,000$0$0$0$0$0
    Net Income$-28,710,000$-23,708,000$-23,461,000$-7,280,000$-30,696,000$148.45M$-46,026,000$-52,956,000$-45,257,000$-43,114,000$-40,243,000$-39,440,000
    EBITDA$-30,595,000$-25,640,000$-28,597,000$-15,242,000$-39,668,000$152.05M$-51,341,000$-57,872,000$-49,983,000$-48,304,000$-43,417,000$-42,796,000
    EBIT$-30,997,000$-26,043,000$-28,997,000$-15,637,000$-40,038,000$151.70M$-52,245,000$-58,749,000$-50,635,000$-48,920,000$-43,999,000$-43,347,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KROS

    News

    Discipline and Rules-Based Execution in KROS Response

    Keros Therapeutics Inc. (NASDAQ: KROS) is showing stable neutral readings in shorter horizons, potentially indicating an easing of a long-term weak bias. An exceptional 89.7:1 risk-reward short setup is identified...

    Stock Traders Daily•10/15/26•Neutral

    Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen

    Wall Street Zen has upgraded Keros Therapeutics (NASDAQ:KROS) from a "strong sell" to a "sell" rating, while the broader analyst consensus remains "Hold" with an average price target of $20.50. The company reported...

    MarketBeat•10/10/26•Somewhat-Bearish

    How (KROS) Movements Inform Risk Allocation Models

    This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) movements, highlighting weak near-term and long-term sentiment with a neutral mid-term outlook. It identifies an exceptional 89.7:1 risk-reward short setup...

    Stock Traders Daily•10/4/26•Bearish

    Keros Therapeutics Inc (KROS-Q) Stock Price and News

    This article provides stock information and recent news for Keros Therapeutics Inc (KROS-Q), a clinical-stage biopharmaceutical company focused on hematological and musculoskeletal disorders. It highlights recent news...

    The Globe and Mail•10/2/26•Neutral

    Keros Therapeutics, Inc. (KROS) Stock Price, News, Quote & History

    Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on developing therapies for disorders related to dysfunctional signaling of the TGF-beta family of proteins. The company's stock...

    Yahoo! Finance Canada•9/30/26•Neutral

    KROS Valuation and Fair Value

    P/E
    -3.0x
    Forward P/E
    48.8x
    P/FCF
    -4.5x
    P/B
    0.8x
    See GNG's fair value

    KROS Profitability: Margins, ROIC and FCF

    Operating margin
    -656.0%
    Net margin
    0.0%
    ROE
    -17.2%
    FCF margin
    -323.0%
    FCF yield
    -22.1%

    KROS Competitors

    CompanyTicker
    InflaRx N.V.IFRX
    MacroGenics IncMGNX
    Pyxis Oncology IncPYXS
    Larimar Therapeutics IncLRMR
    SIGA Technologies IncSIGA
    Owens & Minor IncOMI
    Spok Holdings IncSPOK
    Protalix Biotherapeutics IncPLX

    Sector: Healthcare

    KROS Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    4
    Hold
    3
    Sell
    0
    Strong Sell
    0

    KROS Bull Case vs Bear Case

    Bear case

    • KROS beat EPS estimates in 37.5% of its last 8 reported quarters.
    • KROS's quarterly revenue changed -99.8% year over year.

    KROS Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -33.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.86
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 1 down

    Frequently Asked Questions About KROS

    Does KROS pay dividends?

    Keros Therapeutics Inc (KROS) does not currently pay a regular dividend.

    What is KROS's market cap?

    Keros Therapeutics Inc (KROS) has a market capitalization of $219.09M with a current stock price of $11.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In